Flash | CITI'S TAKE DHR reported 2Q core revenue growth of +3.0%, above FS consensus +2.2% with EPS of $1.94 above consensus $1.84. 2Q Biotechnology revenue was +2.5% core (bioprocessing surprisingly below guidance at +LSD in both equipment and consumables, with +mid-teens order growth in equipment and consumables), Life Sciences grew healthy +5.5% and Diagnostics grew +2.0%. In bioprocessing, a few large commercial customers pushed out revenue late in the quarter leading to the shortfall. 3Q core revenues ...